Application | Comment | Organism |
---|---|---|
synthesis | engineering ERG7 for producing biological active agents is promising | Saccharomyces cerevisiae |
Protein Variants | Comment | Organism |
---|---|---|
C703D | site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme | Saccharomyces cerevisiae |
C703G | site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H | Saccharomyces cerevisiae |
C703H | site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant | Saccharomyces cerevisiae |
C703I | site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant | Saccharomyces cerevisiae |
C703N | site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme | Saccharomyces cerevisiae |
C703S | site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H | Saccharomyces cerevisiae |
C703T | site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H | Saccharomyces cerevisiae |
C703V | site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H | Saccharomyces cerevisiae |
F699A/C703I | site-directed mutagenesis, inactive mutant | Saccharomyces cerevisiae |
F699M/C703I | site-directed mutagenesis, inactive mutant | Saccharomyces cerevisiae |
F699T/C703I | site-directed mutagenesis, different oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are isolated from the mutant | Saccharomyces cerevisiae |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
(3S)-2,3-epoxy-2,3-dihydrosqualene | Saccharomyces cerevisiae | - |
lanosterol | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Saccharomyces cerevisiae | - |
gene ERG7 | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
(3S)-2,3-epoxy-2,3-dihydrosqualene | - |
Saccharomyces cerevisiae | lanosterol | - |
? |
Synonyms | Comment | Organism |
---|---|---|
ERG7 | - |
Saccharomyces cerevisiae |
OSC | - |
Saccharomyces cerevisiae |
Oxidosqualene-lanosterol cyclase | - |
Saccharomyces cerevisiae |
General Information | Comment | Organism |
---|---|---|
physiological function | functional role of the Cys703 residue in stabilizing the bicyclic C-8 cation and the rearranged intermediate or interacting with Phe699 | Saccharomyces cerevisiae |